M.X. Welliver
Ohio State University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by M.X. Welliver.
Molecular Cell | 2013
Michael A. Reid; Wen-I Wang; Kimberly Romero Rosales; M.X. Welliver; Min Pan; Mei Kong
Glutamine is an essential nutrient for cancer cell survival and proliferation, yet the signaling pathways that sense glutamine levels remain uncharacterized. Here, we report that the protein phosphatase 2A (PP2A)-associated protein, α4, plays a conserved role in glutamine sensing. α4 promotes assembly of an adaptive PP2A complex containing the B55α regulatory subunit via providing the catalytic subunit upon glutamine deprivation. Moreover, B55α is specifically induced upon glutamine deprivation in a ROS-dependent manner to activate p53 and promote cell survival. B55α activates p53 through direct interaction and dephosphorylation of EDD, a negative regulator of p53. Importantly, the B55α-EDD-p53 pathway is essential for cancer cell survival and tumor growth under low glutamine conditions in vitro and in vivo. This study delineates a previously unidentified signaling pathway that senses glutamine levels as well as provides important evidence that protein phosphatase complexes are actively involved in signal transduction.
Journal of the National Cancer Institute | 2013
Steven H. Lin; Thomas J. George; Edgar Ben-Josef; Jeffrey D. Bradley; Kevin S. Choe; Martin J. Edelman; Chandan Guha; Sunil Krishnan; Theodore S. Lawrence; Quynh-Thu Le; Bo Lu; Minesh P. Mehta; David M. Peereboom; Jann N. Sarkaria; Jinsil Seong; Dian Wang; M.X. Welliver; C. Norman Coleman; Bhadrasain Vikram; Stephen S. Yoo; Christine H. Chung
The first annual workshop for preclinical and clinical development of radiosensitizers took place at the National Cancer Institute on August 8-9, 2012. Radiotherapy is one of the most commonly applied and effective oncologic treatments for solid tumors. It is well recognized that improved clinical efficacy of radiotherapy would make a substantive impact in clinical practice and patient outcomes. Advances in genomic technologies and high-throughput drug discovery platforms have brought a revolution in cancer treatment by providing molecularly targeted agents for various cancers. Development of predictive biomarkers directed toward specific subsets of cancers has ushered in a new era of personalized therapeutics. The field of radiation oncology stands to gain substantial benefit from these advances given the concerted effort to integrate this progress into radiation therapy. This workshop brought together expert clinicians and scientists working in various disease sites to identify the exciting opportunities and expected challenges in the development of molecularly targeted agents in combination with radiation therapy.
Diagnostic Pathology | 2013
Konstantin Shilo; Xin Wu; Smita Sharma; M.X. Welliver; Wenrui Duan; Miguel A. Villalona-Calero; Junya Fukuoka; Saïd Sif; Robert A. Baiocchi; Charles L. Hitchcock; Weiqiang Zhao; Gregory A. Otterson
BackgroundProtein arginine methyltransferase-5 (PRMT5) is a chromatin-modifying enzyme capable of methylating histone and non-histone proteins, and is involved in a wide range of cellular processes that range from transcriptional regulation to organelle biosynthesis. As such, its overexpression has been linked to tumor suppressor gene silencing, enhanced tumor cell growth and survival.Material and methodsQuantitative real-time polymerase chain reaction, Western immunoblot and immunohistochemistry were used to characterize PRMT5 expression in lung cancer cell lines and human tumors. Clinicopathological findings of tissue microarray based samples from 229 patients with non-small cell lung carcinomas (NSCLC) and 133 cases with pulmonary neuroendocrine tumors (NET) were analyzed with regard to nuclear and cytoplasmic PRMT5 expression.ResultsThere was statistically significant difference in PRMT5 messenger RNA expression between tumors and nonneoplastic lung tissues. Immunoblot experiments showed abundant expression of PRMT5 and its symmetric methylation mark H4R3 in lung carcinoma but not in non-neoplastic human pulmonary alveolar and bronchial epithelial cell lines. More than two thirds of lung tumors expressed PRMT5. High levels of cytoplasmic PRMT5 were detected in 20.5% of NSCLC and in 16.5% of NET; high levels of nuclear PRMT5 were detected in 38.0% of NSCLC and 24.0% of NET. Cytoplasmic PRMT5 was associated with high grade in both NSCLC and pulmonary NET while nuclear PRMT5 was more frequent in carcinoid tumors (p < 0.05).ConclusionThe observed findings support the role of PRMT5 in lung tumorigenesis and reflect its functional dichotomy in cellular compartments.Virtual slideThe virtual slides for this article can be found here:http://www.diagnosticpathology.diagnomx.eu/vs/1611895162102528
Frontiers in Oncology | 2015
Kelly Tyler; Bradley M. Haverkos; Justin Hastings; Eileen Hu; Ramez H. W. Philips; Alejandro A. Gru; M.X. Welliver; Anjali Mishra; Henry K. Wong; Pierluigi Porcu
The clinical benefit of a multidisciplinary clinic practice model has been well described in a variety of medical specialties and cancer types. It proves particularly valuable when an integrated team is needed to optimally manage patients with rare or complex neoplasms. However, the ideal implementation of an integrated multidisciplinary care program for translational research and education has not been well reported. Herein, we propose how a multimodality cutaneous lymphoma (CL) clinic model can optimally manage CL patients. We offer our perspective on this model as an efficient means for delivering patient care, a continuing education resource for referring physicians, a conduit for translational and clinical research, and an educational tool for medical students, house staff, and fellows.
ASCO Meeting Abstracts | 2015
Steven H. Lin; Isabel Mok; David Leos; Manolo G Pasia; Peter F. Thall; Heather Lin; M.X. Welliver; Miguel A. Villalona-Calero; James C. Yao; Funda Meric-Bernstam; R. Komaki; Helen X. Chen; George R. Blumenschein
Blood | 2012
M.X. Welliver; Galena Salem; Amy S. Ruppert; Bradley A. Otto; Robert A. Baiocchi; Pierluigi Porcu
Journal of Thoracic Oncology | 2018
M.X. Welliver; Xiaokui Mo; D. Gunderson; D. Dicostanzo; Patrick Wald; J.G. Bazan; Terence M. Williams; K.E. Haglund; John C. Grecula; Gregory A. Otterson; David P. Carbone
Journal of Clinical Oncology | 2018
Anees M. Dauki; He Lei; Ling Yonghua; Ashley Sekhon; Kari Kendra; Robert Cavaliere; M.X. Welliver; John M. McGregor; Lai Wei; Ewa Mrozek; Thomas Olencki; Julie Thelen; Daniel M. Prevedello; William Thoman; Mani Matharbootham; Mario Ammirati; Christopher C. Coss; John C. Grecula; Mitch A. Phelps
International Journal of Radiation Oncology Biology Physics | 2018
E.D. Miller; J.L. Fisher; K.E. Haglund; John C. Grecula; M.X. Welliver; Erin M. Bertino; K. He; P.G. Shields; David P. Carbone; Terence M. Williams; Gregory A. Otterson; J.G. Bazan
International Journal of Radiation Oncology Biology Physics | 2018
T. Wu; N. Sebastian; Xiaokui Mo; J.G. Bazan; M.X. Welliver; K.E. Haglund; Terence M. Williams